Paulina Mucha-Jagodzinska

W. K. Roentgena 5 Street
Warsaw, MZ 02781, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Corrigendum to 'Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE)': [ESMO Open. Volume 10, Issue 2, February 2025, 104126].

Corrigendum to 'Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE)': [ESMO Open. Volume 10, Issue 2, February 2025, 104126].

Journal: ESMO open

Published: August 05, 2026

Efficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma.

Efficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma.

Journal: Clinical and translational radiation oncology

Published: May 28, 2025

Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).

Health networking on cancer in the European Union: a 'green paper' by the EU Joint Action on Networks of Expertise (JANE).

Journal: ESMO open

Published: September 02, 2024

Diagnostic challenge in chondromyxoid fibroma clinically mimicking neuroma.

Diagnostic challenge in chondromyxoid fibroma clinically mimicking neuroma.

Journal: Contemporary oncology (Poznan, Poland)

Published: May 20, 2024

What role can LAG-3-blocking antibodies play in melanoma therapy?

What role can LAG-3-blocking antibodies play in melanoma therapy?

Journal: Expert opinion on biological therapy

Published: November 08, 2023

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.

Journal: ESMO open

Published: August 30, 2023

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report.

Journal: Cancers

Published: July 05, 2023

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma.

Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma.

Journal: Cancers

Published: January 07, 2022

Mutational landscape of primary and recurrent Ewing sarcoma.

Mutational landscape of primary and recurrent Ewing sarcoma.

Journal: Contemporary oncology (Poznan, Poland)

Published: November 24, 2021

Age as a Prognostic Factor in Patients with Ewing Sarcoma-The Polish Sarcoma Group Experience.

Age as a Prognostic Factor in Patients with Ewing Sarcoma-The Polish Sarcoma Group Experience.

Journal: Journal of clinical medicine

Published: August 07, 2021

The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma.

The clinical prognostic factors and treatment outcomes of adult patients with Ewing sarcoma.

Journal: International journal of clinical oncology

Published: March 15, 2020

High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.

High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.

Journal: Melanoma research

Published: May 22, 2018

Showing 1-12 of 14

Last Updated: 09/26/2026